nach oben

Tipp

Clinical-Pathological Conference Series from the Medical University of Graz

Case No 173: A 77-year-old patient with adenocarcinoma of the prostate, liver metastases and watery diarrhea

Zeitschrift:: Wiener klinische Wochenschrift

Autoren:: MD, PhD, MSc, BSc Elisabeth Fabian, MD Patrizia Kump, MD Dietmar Schiller, MD, PhD Iva Brcic, MD Christine Gruber, MD Philipp U. Heitz, MD Günter Klöppel, MD Rainer W. Lipp, MD Farid Moinfar, MD Rainer Schöfl, MD Peter Fickert, MD, AGAF, MWGO Guenter J. Krejs

» Zum Volltext PDF-Version jetzt herunterladen

Wichtige Hinweise

Information

Information on Clinical-Pathological Conferences from the Medical University of Graz are also available under https://www.medunigraz.at/cpc-klinischpathologischekonferenz/ (in German).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Without Abstract

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Jetzt informieren

TGA Consumer Medical Information (CMI), May 2017, Cosudex ^® 50mg Tablets. AstraZeneca Pty Ltd

TGA Consumer Medical Information (CMI), June 2016, Lucrin ^® 5 mg/ml injection. AbbVie Pty Ltd

TGA Consumer Medical Information (CMI), June 2019, XGEVA ^®. Amgen Australia Pty Ltd

Krejs GJ. VIPoma syndrome. Am J Med. 1987;82(5B):37–48. PubMedCrossRefPubMedCentral

Krejs GJ. Effect of vasoactive intestinal peptide in man. Ann N Y Acad Sci. 1988;527:501–7. PubMedCrossRef

International Agency for Research on Cancer, editor. Digestive system tumors. WHO Classification of tumors. 5th ed. Lyon: International Agency for Research on Cancer; 2019.

Fujiya A, Kato M, Shibata T, Sobajima H. VIPoma with multiple endocrine neoplasia type 1 identified as an atypical gene mutation. BMJ Case Rep. 2015; https://doi.org/10.1136/bcr-2015-213016. CrossRefPubMedPubMedCentral

Faugeroux V, Pailler E, Oulhen M, Deas O, Brulle-Soumare L, Hervieu C, et al. Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model. Nat Commun. 2020;11(1):1884. PubMedPubMedCentralCrossRef

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54. PubMedCrossRef

10.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. PubMedPubMedCentralCrossRef

11.

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33. PubMedPubMedCentralCrossRef

12.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel‑T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. PubMedCrossRefPubMedCentral

13.

Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. PubMedCrossRefPubMedCentral

14.

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20. PubMedCrossRefPubMedCentral

15.

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298–305. PubMedPubMedCentralCrossRef

16.

Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487–95. PubMedPubMedCentralCrossRef

17.

Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38(6):756–67. PubMedPubMedCentralCrossRef

18.

Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer. 2005;12(1):109–17. PubMedCrossRefPubMedCentral

19.

Sarkar D, Singh SK, Mandal AK, Agarwal MM, Mete UK, Kumar S, et al. Plasma chromogranin a: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy. Cancer Biomark. 2011;8(2):81–7. CrossRef

20.

Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E, et al. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer. 2014;21(3):487–93. PubMedCrossRef

21.

Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, et al. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate. 2014;74(16):1691–6. PubMedCrossRef

22.

Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, et al. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res. 2008;68(23):9663–70. PubMedPubMedCentralCrossRef

23.

Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 2005;47(2):147–55. PubMedCrossRef

24.

Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest. 2005;28(11 Suppl Int):141–5. PubMed

25.

Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr, Evans CP. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(1):6–14. PubMedCrossRef

26.

Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol. 2015;5:90. PubMedPubMedCentralCrossRef

27.

Vanoverberghe K, Vanden Abeele F, Mariot P, Lepage G, Roudbaraki M, Bonnal JL, et al. Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ. 2004;11(3):321–30. PubMedCrossRef

28.

Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer. 2007;14(3):531–47. PubMedCrossRef

29.

Mutt V. Isolation and structure of vasoactive intestinal polypeptide from various species. In: Said SI, editor. Vasoactive intestinal peptide. New York: Raven Press; 1982. pp. 1–10.

30.

Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169(3951):1217–8. PubMedCrossRefPubMedCentral

31.

Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature. 1970;225(5235):863–4. PubMedCrossRefPubMedCentral

32.

Grossman M, Brown JC, Said S, Adelson J, Rothman SS, Li TM, et al. Candidate hormones of the gut. Gastroenterology. 1974;67(4):730–55. PubMedCrossRefPubMedCentral

33.

Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med. 1958;25(3):374–80. PubMedCrossRefPubMedCentral

34.

Zollinger R, Ellison EH. Primary peptic ulceration of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955;142(4):709–23. PubMedPubMedCentralCrossRef

35.

Bloom SR, Polak JM, Pearse AG. Vasoactive intestinal peptide and watery-diarrhoea syndrome. Lancet. 1973;2(7819):14–6. PubMedCrossRefPubMedCentral

36.

Said SI, Faloona GR, Harvey S, Deon H, Ford WT. Elevated plasma and tissue levels of vasoactive intestinal polypeptide in the watery-diarrhea syndrome due to pancreatic, bronchogenic and other tumors. N Engl J Med. 1975;293(4):155–60. PubMedCrossRefPubMedCentral

37.

Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumors: the current incidence and staging based on the WHO and European Neuroendocrine tumor Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–18. PubMedCrossRefPubMedCentral

38.

Krejs GJ, Fordtran JS. Diarrhea. In: Sleisenger M, Fordtran JS, editors. Gastrointestinal disease. 3rd ed. Philadelphia: WB Saunders; 1983. pp. 257–80.

39.

Holm-Bentzen M, Christiannsen J, Petersen B, Fahrenkrug J, Schultz A, Kirkegaard P. Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion. Scand J Gastroent. 1981;16(3):429–32. PubMedCrossRefPubMedCentral

40.

Kane MG, O’Dorisio TM, Krejs GJ. Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide. N Engl J Med. 1983;309(24):1482–5. PubMedCrossRefPubMedCentral

41.

Krejs GJ, Hendler RS, Fordtran JS. Diagnostic and pathophysiologic studies in patients with chronic diarrhea. In: Field M, editor. Secretory diarrhea. Bethesda: American Physiologic Society; 1980. pp. 141–51.

42.

Krejs GJ. Effect of somatostatin infusion on VIP-induced transport changes in the human jejunum. Peptides. 1984;5(2):271–6. PubMedCrossRefPubMedCentral

43.

Krejs GJ, Barkley RM, Read NW, Fordtran JS. Intestinal secretion induced by vasoactive intestinal polypeptide. A comparison with cholera toxin in the canine jejunum in vivo. J Clin Invest. 1978;61(5):1337–45. PubMedPubMedCentralCrossRef

44.

Santangelo WC, O’Dorisio TM, Kim JG, Severino G, Krejs GJ. Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport. Ann Int Med. 1985;103(3):363–7. PubMedCrossRefPubMedCentral

45.

Fabian E, Kump P, Krejs GJ. Diarrhea caused by circulating agents. Gastroenterol Clin North Am. 2012;41(3):603–10. PubMedCrossRefPubMedCentral

46.

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63. CrossRef

47.

Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33. CrossRef

48.

Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charbonneau JW, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50(18):5969–77. PubMed

49.

Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumors. J Clin Oncol. 2009;27(28):4656–63. CrossRef

50.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. NETTER‑1 Trial Investigators. N Engl J Med. 2017;376(2):125–35. PubMedPubMedCentralCrossRef

51.

Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13. CrossRef

52.

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumors of the lung, gastrointestinal tract (RADIANT-4): a randomized, placebo-controlled phase 3 study. Lancet. 2016;387(10022):968–77. PubMedCrossRefPubMedCentral

53.

Krug S, Boch M, Daniel H, Nimphius W, Müller D, Michl P, et al. Streptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms: predictive and prognostic markers for treatment stratification. PLoS ONE. 2015;10(12):e143822. PubMedPubMedCentralCrossRef

Titel: Clinical-Pathological Conference Series from the Medical University of Graz
Case No 173: A 77-year-old patient with adenocarcinoma of the prostate, liver metastases and watery diarrhea
Autoren:: MD, PhD, MSc, BSc Elisabeth Fabian
MD Patrizia Kump
MD Dietmar Schiller
MD, PhD Iva Brcic
MD Christine Gruber
MD Philipp U. Heitz
MD Günter Klöppel
MD Rainer W. Lipp
MD Farid Moinfar
MD Rainer Schöfl
MD Peter Fickert
MD, AGAF, MWGO Guenter J. Krejs
Publikationsdatum: 04.01.2021
DOI: https://doi.org/10.1007/s00508-020-01791-x
Verlag: Springer Vienna
Zeitschrift: Wiener klinische Wochenschrift The Central European Journal of Medicine
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671